Differences in invasiveness and recurrence rate among nonfunctioning pituitary neuroendocrine tumors depending on tumor subtype.
Cavernous sinus invasion
Dura mater defect
GATA3
Invasiveness
Pituitary neuroendocrine tumor
Recurrence
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
30 Nov 2023
30 Nov 2023
Historique:
received:
12
09
2023
accepted:
26
11
2023
revised:
22
11
2023
medline:
1
12
2023
pubmed:
30
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
To clarify the invasiveness to surrounding structures and recurrence rate of each subtype of nonfunctioning pituitary neuroendocrine tumor (Pit-NETs) according to the WHO 2022 classification. This retrospective study utilized data from 292 patients with nonfunctioning Pit-NETs treated with initial transsphenoidal surgery. Recurrence was evaluated on 113 patients who were available for a magnetic resonance imaging follow-up ≥ 60 months. All tumors were assessed by immunohistochemical staining for Pit-1, T-PIT, and GATA3. Invasiveness to surrounding structures was evaluated based on intraoperative findings. Cavernous sinus invasion was found in 47.5% of null cell tumors, 50.0% of Pit-1 lineage tumors, 31.8% of corticotroph tumors, and 18.3% of gonadotroph tumors. Dura mater defects in the floor of sellar turcica, indicating dural invasion, were found in 44.3% of null cell tumors, 36.4% of corticotroph tumors, 16.7% of Pit-1 lineage tumors, and 17.3% of gonadotroph tumors. In logistic regression analysis, Pit-1 (OR 5.90, 95% CI 1.71-20.4, P = 0.0050) and null tumors (OR 4.14, 95% CI 1.86-9.23, P = 0.0005) were associated with cavernous sinus invasion. Recurrence was found in 8 (4.9%) patients, but without significant differences between tumor subtypes. The presence of cavernous sinus invasion was correlated with recurrence (HR = 1.95, 95% CI 1.10-3.46, P = 0.0227). Among nonfunctioning Pit-NETs, Pit-1 lineage tumors tend to invade the cavernous sinus, corticotroph tumors may produce dura mater defects, and null cell tumors tend to cause both. Pit-NETs with cavernous sinus invasion require a careful attention to recurrence.
Identifiants
pubmed: 38030890
doi: 10.1007/s10143-023-02234-7
pii: 10.1007/s10143-023-02234-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317Subventions
Organisme : JSPS Grant-in-Aid for Scientific Research (C)
ID : JP23K06697
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
(2014) Brain tumor registry of Japan (2001–2004). Neurol Med Chir (Tokyo) 54(Suppl):1–102. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740110/
Asa SL, Mete O, Perry A, Osamura RY (2022) Overview of the 2022 WHO classification of pituitary tumors. Endocr Pathol 33:6–26. https://doi.org/10.1007/s12022-022-09703-7
doi: 10.1007/s12022-022-09703-7
pubmed: 35291028
Nishioka H (2023) Aggressive pituitary tumors (PitNETs). Endocr J 70:241–248. https://doi.org/10.1507/endocrj.EJ23-0007
doi: 10.1507/endocrj.EJ23-0007
pubmed: 36858483
Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135. https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
Ntali G, Wass JA (2018) Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 21:111–118. https://doi.org/10.1007/s11102-018-0869-3
doi: 10.1007/s11102-018-0869-3
pubmed: 29368293
Trouillas J, Jaffrain-Rea ML, Vasiljevic A, Raverot G, Roncaroli F, Villa C (2020) How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020. Cancers (Basel) 12:514. https://doi.org/10.3390/cancers12020514
doi: 10.3390/cancers12020514
pubmed: 32098443
Yamada S, Ohyama K, Taguchi M et al (2007) A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61:580–584. https://doi.org/10.1227/01.NEU.0000290906.53685.79
doi: 10.1227/01.NEU.0000290906.53685.79
pubmed: 17881972
Nishioka H, Inoshita N, Mete O et al (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26:349–355. https://doi.org/10.1007/s12022-015-9398-z
doi: 10.1007/s12022-015-9398-z
pubmed: 26481628
Haddad AF, Young JS, Oh T et al (2020) Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution. Neurosurg Focus 48:E13. https://doi.org/10.3171/2020.3.FOCUS20114
doi: 10.3171/2020.3.FOCUS20114
pubmed: 32480370
Taguchi A, Kinoshita Y, Tokumo K et al (2022) Usefulness of critical flicker fusion frequency measurement and its laterality for evaluating compressive optic neuropathy due to pituitary neuroendocrine tumors. Neurosurg Rev 46:4. https://doi.org/10.1007/s10143-022-01915-z
doi: 10.1007/s10143-022-01915-z
pubmed: 36471083
Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: A magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617. https://doi.org/10.1227/00006123-199310000-00008
doi: 10.1227/00006123-199310000-00008
pubmed: 8232800
Kinoshita Y, Tominaga A, Usui S et al (2016) The surgical side effects of pseudocapsular resection in nonfunctioning pituitary adenomas. World Neurosurg 93:430–435. https://doi.org/10.1016/j.wneu.2016.07.036
doi: 10.1016/j.wneu.2016.07.036
pubmed: 27443228
Mete O, Kefeli M, Çalışkan S, Asa SL (2019) GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. Mod Pathol 32:484–489. https://doi.org/10.1038/s41379-018-0167-7
doi: 10.1038/s41379-018-0167-7
pubmed: 30390035
Turchini J, Sioson L, Clarkson A, Sheen A, Gill AJ (2020) Utility of GATA-3 expression in the analysis of pituitary neuroendocrine tumour (PitNET) transcription factors. Endocr Pathol 31:150–155. https://doi.org/10.1007/s12022-020-09615-4
doi: 10.1007/s12022-020-09615-4
pubmed: 32193825
Mayson SE, Snyder PJ (2014) Silent (clinically nonfunctioning) pituitary adenomas. J Neurooncol 117:429–436. https://doi.org/10.1007/s11060-014-1425-2
doi: 10.1007/s11060-014-1425-2
pubmed: 24676675
Jiang S, Zhu J, Feng M et al (2021) Clinical profiles of silent corticotroph adenomas compared with silent gonadotroph adenomas after adopting the 2017 WHO pituitary classification system. Pituitary 24:564–573. https://doi.org/10.1007/s11102-021-01133-8
doi: 10.1007/s11102-021-01133-8
pubmed: 33651318
Anat Ben-Shlomo SM (2011) Chapter 2: Hypothalamic regulation of anterior pituitary function. In: Anat Ben-Shlomo, Shlomo Melmed. (ed) The Pituitary (Third edition), pp. 21–45. Academic Press (2011), https://www.academia.edu/19700586/The_Pituitary_3rd_Edition . Accessed 22 June 2023.
Perez-Rivas LG, Simon J, Albani A et al (2022) TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun 10:139. https://doi.org/10.1186/s40478-022-01437-1
doi: 10.1186/s40478-022-01437-1
pubmed: 36123588
pmcid: 9484083
McCormack A, Dekkers OM, Petersenn S et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178:265–276. https://doi.org/10.1530/EJE-17-0933
doi: 10.1530/EJE-17-0933
pubmed: 29330228
Asmaro K, Zhang M, Rodrigues AJ et al (2023) Cytodifferentiation of pituitary tumors influences pathogenesis and cavernous sinus invasion. J Neurol Surg 28:1–9. https://doi.org/10.3171/2023.3.JNS221949
doi: 10.3171/2023.3.JNS221949
Nishioka H, Fukuhara N, Horiguchi K, Yamada S (2014) Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. J Neurosurg 121:505–510. https://doi.org/10.3171/2014.3.JNS132214
doi: 10.3171/2014.3.JNS132214
pubmed: 25014437
Langlois F, Woltjer R, Cetas JS, Fleseriu M (2018) Silent somatotroph pituitary adenomas: an update. Pituitary 21:194–202. https://doi.org/10.1007/s11102-017-0858-y
doi: 10.1007/s11102-017-0858-y
pubmed: 29305680
Cossu G, Daniel RT, Pierzchala K et al (2019) Thyrotropin-secreting pituitary adenomas: a systematic review and meta-analysis of postoperative outcomes and management. Pituitary 22:79–88. https://doi.org/10.1007/s11102-018-0921-3
doi: 10.1007/s11102-018-0921-3
pubmed: 30390277
Taguchi A, Kinoshita Y, Yamasaki F, Arita K, Tominaga A (2021) Clinical characteristics and thyroid hormone dynamics of thyrotropin-secreting pituitary adenomas at a single institution. Endocrine 73:151–159. https://doi.org/10.1007/s12020-020-02556-2
doi: 10.1007/s12020-020-02556-2
pubmed: 33283257
Yamada S, Fukuhara N, Horiguchi K et al (2014) Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 121:1462–1473. https://doi.org/10.3171/2014.7.JNS1471
doi: 10.3171/2014.7.JNS1471
pubmed: 25237847
Trouillas J, Delgrange E, Wierinckx A et al (2019) Clinical, pathological, and molecular factors of aggressiveness in lactotroph tumours. Neuroendocrinology 109:70–76. https://doi.org/10.1159/000499382
doi: 10.1159/000499382
pubmed: 30943495
Mohyeldin A, Katznelson LJ, Hoffman AR et al (2022) Prospective intraoperative and histologic evaluation of cavernous sinus medial wall invasion by pituitary adenomas and its implications for acromegaly remission outcomes. Sci Rep 12:9919. https://doi.org/10.1038/s41598-022-12980-1
doi: 10.1038/s41598-022-12980-1
pubmed: 35705579
pmcid: 9200976
Lee JC, Pekmezci M, Lavezo JL et al (2017) Utility of Pit-1 immunostaining in distinguishing pituitary adenomas of primitive differentiation from null cell adenomas. Endocr Pathol 28:287–292. https://doi.org/10.1007/s12022-017-9503-6
doi: 10.1007/s12022-017-9503-6
pubmed: 28994039
Lloyd RV, Landefeld TD, Maslar I, Frohman LA (1985) Diethylstilbestrol inhibits tumor growth and prolactin production in rat pituitary tumors. Am J Pathol 118:379–386
pubmed: 3976841
pmcid: 1887947
Ishida A, Shiramizu H, Yoshimoto H et al (2022) Resection of the cavernous sinus medial wall improves remission rate in functioning pituitary tumors: retrospective analysis of 248 consecutive cases. Neurosurgery 91:775–781. https://doi.org/10.1227/neu.0000000000002109
doi: 10.1227/neu.0000000000002109
pubmed: 36001781
Zhao J, Ji C, Cheng H et al (2023) Digital image analysis allows objective stratification of patients with silent PIT1-lineage pituitary neuroendocrine tumors. J Pathol Clin Res 9:488–497. https://doi.org/10.1002/cjp2.340
doi: 10.1002/cjp2.340
pubmed: 37661840
pmcid: 10556262
Lenders NF, Earls PE, Wilkinson AC et al (2023) Predictors of pituitary tumour behaviour: an analysis from long-term follow-up in 2 tertiary centres. Eur J Endocrinol 189:106–114. https://doi.org/10.1093/ejendo/lvad079
doi: 10.1093/ejendo/lvad079
pubmed: 37461224
Tadokoro K, Wolf C, Toth J et al (2022) Ki-67/MIB-1 and recurrence in pituitary adenoma. J Neurol Surg B Skull Base 83(Suppl 2):e580–e590. https://doi.org/10.1055/s-0041-1735874
doi: 10.1055/s-0041-1735874
pubmed: 35832982
Ng S, Messerer M, Engelhardt J et al (2021) Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien) 163:3131–3142. https://doi.org/10.1007/s00701-021-04953-6
doi: 10.1007/s00701-021-04953-6
pubmed: 34365544